Article
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.
BMJ open - 5 Jul 2024
Robledo Kristy P, Lefresne Shilo, Soon Yu Yang, Sahgal Arjun, Pinkham Mark B, Nichol Alan, Soo Ross Andrew, Parmar Ambika, Hegi-Johnson Fiona, Doherty Mark, Solomon Benjamin J, Shultz David B, Tham Ivan Wk, Sacher Adrian G, Tey Jeremy, Leong Cheng Nang, Koh Wee Yao, Huang Yiqing, Ang Yvonne Li En, Low Jiali, Yong Clement, Lim Mei Chin, Tan Ai Peng, Lee Chee Khoon, Ho Cheryl
Abstract excerpt
BACKGROUND: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene are a heterogeneous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer-generation targeted therapies in the central nervous system. We present a protocol for...
Topics
Join the communities discussing this publication.